CA1269659A
(en)
*
|
1984-08-06 |
1990-05-29 |
Brigham Young University |
Method for the production of 2'-deoxyadenosine compounds
|
CA1295998C
(en)
*
|
1985-07-29 |
1992-02-18 |
Sai P. Sunkara |
Nucleosides and their use as antineoplastic agents
|
US4814438A
(en)
*
|
1986-12-24 |
1989-03-21 |
Eli Lilly And Company |
Immunoglobulin conjugates of 2',2'-difluronucleosides
|
US4994558A
(en)
*
|
1986-12-24 |
1991-02-19 |
Eli Lilly And Company |
Immunoglobulin conjugates
|
IL84842A0
(en)
*
|
1986-12-24 |
1988-06-30 |
Lilly Co Eli |
Immunoglobulin conjugates
|
EP0688783B1
(en)
*
|
1987-08-28 |
2001-06-13 |
Eli Lilly And Company |
Method for preparing 2'-deoxy-2',2'-difluornucleosides
|
US5223608A
(en)
*
|
1987-08-28 |
1993-06-29 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
US4965374A
(en)
*
|
1987-08-28 |
1990-10-23 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
US4914028A
(en)
*
|
1988-02-10 |
1990-04-03 |
Eli Lilly And Company |
Method of preparing beta-2',2'-difluoronucleosides
|
US5644043A
(en)
*
|
1988-02-16 |
1997-07-01 |
Eli Lilly And Company |
2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
|
ES2075040T3
(es)
*
|
1988-02-16 |
1995-10-01 |
Lilly Co Eli |
2',3'-dideoxi-2',2'-difluoronucleosidos.
|
US4996308A
(en)
*
|
1988-03-25 |
1991-02-26 |
Merrell Dow Pharmaceuticals Inc. |
Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
|
JPH0232093A
(ja)
*
|
1988-06-08 |
1990-02-01 |
Merrell Dow Pharmaceut Inc |
抗レトロウィルスジフルオロ化ヌクレオシド類
|
CA2004695C
(en)
*
|
1988-12-12 |
1999-08-10 |
Rosanne Bonjouklian |
Phospholipid nucleosides
|
YU43193A
(sh)
*
|
1992-06-22 |
1997-01-08 |
Eli Lilly And Company |
2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
|
AU4134793A
(en)
*
|
1992-06-22 |
1993-12-23 |
Eli Lilly And Company |
2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
|
AU671491B2
(en)
*
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
US5424416A
(en)
*
|
1993-08-25 |
1995-06-13 |
Eli Lilly And Company |
Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
|
US5480992A
(en)
*
|
1993-09-16 |
1996-01-02 |
Eli Lilly And Company |
Anomeric fluororibosyl amines
|
US5637688A
(en)
|
1994-12-13 |
1997-06-10 |
Eli Lilly And Company |
Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
|
US5559222A
(en)
*
|
1995-02-03 |
1996-09-24 |
Eli Lilly And Company |
Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
|
NZ336676A
(en)
*
|
1997-01-24 |
2000-01-28 |
Norsk Hydro As |
Gemcitabine esters or amides useful as anti-cancer and anti-viral agents
|
AU6473098A
(en)
*
|
1997-03-24 |
1998-10-20 |
Eli Lilly And Company |
Difluoronucleoside phosphonic acids and derivatives thereof
|
TW466112B
(en)
*
|
1998-04-14 |
2001-12-01 |
Lilly Co Eli |
Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
|
US6326507B1
(en)
*
|
1998-06-19 |
2001-12-04 |
Trustees Of Dartmouth College |
Therapeutic compounds and methods of use
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
AU5717400A
(en)
*
|
1999-06-14 |
2001-01-02 |
Cancer Research Ventures Limited |
Cancer therapy
|
WO2002009700A1
(en)
*
|
2000-07-28 |
2002-02-07 |
Cancer Research Technology Limited |
Cancer treatment by combination therapy
|
GB0019124D0
(en)
*
|
2000-08-03 |
2000-09-27 |
Pfizer |
Novel process
|
HU230302B1
(hu)
*
|
2000-10-20 |
2015-12-28 |
Eisai R&D Management Co., Ltd. |
Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
|
US20050250854A1
(en)
*
|
2000-11-03 |
2005-11-10 |
Amgen Inc. |
Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
|
WO2002039958A2
(en)
*
|
2000-11-03 |
2002-05-23 |
Tularik Inc. |
Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
|
US7435755B2
(en)
|
2000-11-28 |
2008-10-14 |
The Trustees Of Dartmouth College |
CDDO-compounds and combination therapies thereof
|
GB0121285D0
(en)
*
|
2001-09-03 |
2001-10-24 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
US20030139373A1
(en)
*
|
2001-11-20 |
2003-07-24 |
Breimer Lars Holger |
Method for cancer therapy
|
US7365167B2
(en)
*
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
US7390885B2
(en)
*
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
RU2346686C2
(ru)
*
|
2002-01-14 |
2009-02-20 |
Новартис Аг |
Комбинации, включающие эпотилоны и антиметаболиты
|
EP1465615B1
(en)
*
|
2002-01-15 |
2012-08-01 |
Trustees of Dartmouth College |
Tricyclic-bis-enone derivatives and methods of use thereof
|
BR0307712A
(pt)
*
|
2002-02-14 |
2005-05-24 |
Pharmasset Ltd |
Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
|
GB2386836B
(en)
*
|
2002-03-22 |
2006-07-26 |
Cancer Res Ventures Ltd |
Anti-cancer combinations
|
GB0223380D0
(en)
*
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
GB2394658A
(en)
*
|
2002-11-01 |
2004-05-05 |
Cancer Rec Tech Ltd |
Oral anti-cancer composition
|
US7994159B2
(en)
*
|
2003-03-10 |
2011-08-09 |
Eisai R&D Management Co., Ltd. |
c-Kit kinase inhibitor
|
AU2003233586A1
(en)
*
|
2003-05-20 |
2005-01-21 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising capecitabine and a liposomal platinum complex
|
CA2525952A1
(en)
*
|
2003-05-20 |
2004-12-09 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
|
DE10323279A1
(de)
*
|
2003-05-21 |
2004-12-16 |
Stada Arzneimittel Ag |
Gebrauchsfertige Gemcitabin-Lösungen
|
GB0321999D0
(en)
*
|
2003-09-19 |
2003-10-22 |
Cancer Rec Tech Ltd |
Anti-cancer combinations
|
CN101337930B
(zh)
*
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
CN1917885A
(zh)
|
2004-02-06 |
2007-02-21 |
施瑞修德制药公司 |
抗癌疗法
|
PT1763356E
(pt)
*
|
2004-04-22 |
2008-09-05 |
Lilly Co Eli |
Composição compreendendo um oligonucleótido anti-sentido de survivina e gemcitabina para o tratamento do cancro
|
ATE428421T1
(de)
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
US20060089329A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Edgar Schridde |
Ready-to-use gemcitabine solution concentrates
|
US20060089328A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Edgar Schridde |
Ready-to-use gemcitabine solutions
|
US7563570B2
(en)
*
|
2004-10-29 |
2009-07-21 |
Pangaea Biotech |
Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
|
JP2007522151A
(ja)
*
|
2004-12-08 |
2007-08-09 |
シコール インコーポレイティド |
ジフルオロヌクレオシド及びその調製方法
|
DE102004063347A1
(de)
*
|
2004-12-23 |
2006-07-13 |
Stada Arzneimittel Ag |
Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
|
MY142304A
(en)
|
2005-01-31 |
2010-11-15 |
Taiho Pharmaceutical Co Ltd |
Novel pyrimidine nucleoside compound or salt thereof
|
JP2008531680A
(ja)
*
|
2005-03-04 |
2008-08-14 |
ダブール・ファーマ・リミテッド |
βアノマーが富化された21−デオキシ−21,21−ジフルオロ−D−リボフラノシルヌクレオシドの調製のための中間体と方法
|
WO2006119347A1
(en)
|
2005-05-02 |
2006-11-09 |
Pharmaessentia Corp. |
STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
|
US20100105031A1
(en)
*
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
AU2006283174A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Cell-Matrix, Inc. |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
AU2006283371A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Antisoma Research Limited |
Combinations comprising DMXAA for the treatment of cancer
|
CA2627598C
(en)
*
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
WO2007061127A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
RU2448708C3
(ru)
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
EP2045256A4
(en)
|
2006-07-21 |
2009-09-02 |
Taiho Pharmaceutical Co Ltd |
2'CYANOPYRIMIDINE NUCLEOSIDE COMPOUND
|
KR101426101B1
(ko)
|
2006-07-24 |
2014-08-13 |
다이호야쿠힌고교 가부시키가이샤 |
3'-에티닐시티딘 유도체
|
KR101472600B1
(ko)
*
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
CA2670099A1
(en)
*
|
2006-11-17 |
2008-05-29 |
Trustees Of Dartmouth College |
Synthesis and biological activities of new tricyclic-bis-enones (tbes)
|
WO2008064132A2
(en)
*
|
2006-11-17 |
2008-05-29 |
Trustees Of Dartmouth College |
Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
|
US8921340B2
(en)
|
2006-11-17 |
2014-12-30 |
Trustees Of Dartmouth College |
Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
|
JPWO2008088088A1
(ja)
|
2007-01-19 |
2010-05-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
膵癌治療用組成物
|
WO2008093855A1
(ja)
*
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
WO2008124691A1
(en)
*
|
2007-04-05 |
2008-10-16 |
Threshold Pharmaceuticals, Inc. |
Glufosfamide combination therapy
|
WO2009023845A2
(en)
*
|
2007-08-15 |
2009-02-19 |
The Board Of Regents Of The University Of Texas System |
Combination therapy with synthetic triterpenoids and gemcitabine
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
AU2008323923A1
(en)
|
2007-11-06 |
2009-05-14 |
Pharmaessentia Corporation |
Novel synthesis of beta-nucleosides
|
US8603998B2
(en)
|
2007-11-07 |
2013-12-10 |
Merck Sharp & Dohme Corp. |
Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
|
WO2009060945A1
(ja)
|
2007-11-09 |
2009-05-14 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
EA022166B1
(ru)
*
|
2008-01-11 |
2015-11-30 |
Ритэ Фамэсутиклс, Инк. |
Синтетические тритерпеноиды и их применение в лечении заболеваний
|
WO2009096377A1
(ja)
*
|
2008-01-29 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
血管阻害物質とタキサンとの併用
|
TW201004627A
(en)
|
2008-04-18 |
2010-02-01 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
CN102164941B
(zh)
|
2008-04-18 |
2015-05-27 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
|
CN102083442B
(zh)
|
2008-04-18 |
2014-08-13 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:在c-17具有氨基和其它修饰的齐墩果酸衍生物
|
CA2721665C
(en)
|
2008-04-18 |
2017-01-24 |
Reata Pharmaceuticals, Inc. |
Compounds including an anti-inflammatory pharmacore and methods of use
|
US7943778B2
(en)
|
2008-04-18 |
2011-05-17 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
|
US9198893B2
(en)
|
2008-05-22 |
2015-12-01 |
Galera Labs, Llc |
Combination antitumor therapy
|
US8314137B2
(en)
*
|
2008-07-22 |
2012-11-20 |
Trustess Of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
WO2010019396A1
(en)
*
|
2008-08-13 |
2010-02-18 |
Threshold Pharmaceuticals, Inc. |
Administration of glufosfamide for the treatment of cancer
|
US8609631B2
(en)
|
2009-04-06 |
2013-12-17 |
Eisai Inc. |
Compositions and methods for treating cancer
|
US8324180B2
(en)
*
|
2009-04-06 |
2012-12-04 |
Eisai Inc. |
Compositions and methods for treating cancer
|
ES2628609T3
(es)
*
|
2009-04-06 |
2017-08-03 |
Otsuka Pharmaceutical Co., Ltd. |
Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
|
CA2757744C
(en)
*
|
2009-04-06 |
2018-02-13 |
Eisai Inc. |
Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
|
GB0907551D0
(en)
|
2009-05-01 |
2009-06-10 |
Univ Dundee |
Treatment or prophylaxis of proliferative conditions
|
WO2011028638A1
(en)
|
2009-09-04 |
2011-03-10 |
Schering Corporation |
Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
|
CN102947302A
(zh)
|
2010-02-18 |
2013-02-27 |
西班牙国家癌症研究中心 |
三唑并[4,5-b]吡啶衍生物
|
WO2011116026A2
(en)
|
2010-03-15 |
2011-09-22 |
The Board Of Trustees Of The University Of Illinois |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
WO2011143590A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
|
WO2011143593A1
(en)
|
2010-05-14 |
2011-11-17 |
Cornerstone Pharmaceuticals, Inc. |
Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
|
US8530444B2
(en)
*
|
2010-06-01 |
2013-09-10 |
Aposense Ltd. |
Pharmaceutical compounds
|
US9192680B2
(en)
|
2010-06-01 |
2015-11-24 |
Aposense Ltd. |
Pharmaceutical compounds
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
WO2012069972A1
(en)
|
2010-11-19 |
2012-05-31 |
Piramal Life Sciences Limited |
A pharmaceutical combination for the treatment of breast cancer
|
EP2655401B1
(en)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
WO2012123889A1
(en)
|
2011-03-14 |
2012-09-20 |
Piramal Healthcare Limited |
A synergistic pharmaceutical combination for the treatment of pancreatic cancer
|
EP2694072B1
(en)
|
2011-04-01 |
2017-11-29 |
Genentech, Inc. |
Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
RS57449B1
(sr)
|
2012-04-04 |
2018-09-28 |
Halozyme Inc |
Kombinovana terapija sa hijaluronidazom i taksanom koji ciljno deluje na tumor
|
US8921419B2
(en)
|
2012-05-08 |
2014-12-30 |
Trustees Of Dartmouth College |
Triterpenoids and compositions containing the same
|
AU2013273489B9
(en)
|
2012-06-08 |
2018-08-23 |
F. Hoffmann-La Roche Ag |
Mutant selectivity and combinations of a phosphoinositide 3 Kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
CN104428006B
(zh)
|
2012-07-04 |
2017-09-08 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原‑抗体缀合物
|
EP2711008A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
|
EP2711007A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
|
EP2711009A1
(en)
|
2012-09-19 |
2014-03-26 |
Institut Univ. de Ciència i Tecnologia, S.A. |
Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
|
WO2014078522A1
(en)
|
2012-11-14 |
2014-05-22 |
Ohio State Innovation Foundation |
Materials and methods useful for treating glioblastoma
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
MX368099B
(es)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
|
WO2015191576A1
(en)
|
2014-06-09 |
2015-12-17 |
Lipomedix Pharmaceuticals Ltd. |
Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
|
MX2016015280A
(es)
|
2014-06-26 |
2017-03-03 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
WO2016078160A1
(zh)
*
|
2014-11-17 |
2016-05-26 |
常州方圆制药有限公司 |
胞苷衍生物及其应用
|
EP3250609A4
(en)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra alpha 2 binding agents and use thereof in cancer treatment
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
BR112017017428A2
(pt)
|
2015-02-25 |
2018-04-03 |
Eisai R&D Management Co., Ltd. |
?método para supressão do amargor de derivado de quinolina?
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
CN106317147B
(zh)
*
|
2015-07-06 |
2018-11-27 |
扬州硒瑞恩生物医药科技有限公司 |
核苷类化合物及其制备方法
|
US20200306254A1
(en)
|
2016-06-29 |
2020-10-01 |
Eli Lilly And Company |
Combination of erk1/2 inhibitor compound with gemcitabine or with gemcitabine and nab-paclitaxel for use in treatment of pancreatic cancer
|
CN110248673A
(zh)
|
2016-11-21 |
2019-09-17 |
百祥制药公司 |
用于治疗胰腺癌的包括SapC-DOPS的联合疗法
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
AU2018314227A1
(en)
|
2017-08-07 |
2020-02-06 |
Amgen Inc. |
Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus
|
BR112020005196A2
(pt)
|
2017-09-18 |
2020-09-15 |
The Regents Of The University Of California |
anticorpos claudin6 e métodos para tratar câncer
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
PE20210367A1
(es)
|
2018-02-02 |
2021-02-26 |
Maverix Oncology Inc |
Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
EP3820879A4
(en)
|
2018-06-29 |
2022-04-13 |
Shanghai Changchengyiyaokeji Company Limited |
GEMCITABINE PHOSPHORUS-CONTAINING PRODRUGS
|
WO2020058405A1
(en)
|
2018-09-20 |
2020-03-26 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
WO2020144657A1
(en)
|
2019-01-11 |
2020-07-16 |
Lipomedix Pharmaceuticals Ltd. |
Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
WO2020191344A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
AU2020266083A1
(en)
|
2019-04-30 |
2021-09-23 |
Instituto de Medicina Molecular João Lobo Antunes |
Rank pathway inhibitors in combination with CDK inhibitors
|
EP3980541A1
(en)
|
2019-06-04 |
2022-04-13 |
Apterna Limited |
Aptamers against transferrin receptor (tfr)
|
US20220305081A1
(en)
|
2019-06-24 |
2022-09-29 |
Amgen Inc. |
Inhibitions of sirp-gamma for cancer treatment
|
CN110684062B
(zh)
*
|
2019-10-18 |
2022-12-13 |
大连大学 |
一种治疗非小细胞肺癌的药物及其制备方法
|
GB202019692D0
(en)
|
2020-12-14 |
2021-01-27 |
Apterna Ltd |
Aptamer-sirna fusions
|